GlassScriptPhysician profile
Dafang Chen
NPI 1710341433
$6,748.26
in general payments reported to CMS, 2019-2025
31 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $304 · 2023: $5,050 · 2024: $605 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,037 · Food and Beverage: $2,148 · Travel and Lodging: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,037.38 |
| Food and Beverage | $2,147.57 |
| Travel and Lodging | $1,259.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,417.08 | 2023 | Ion, Da Vinci Surgical System |
| Insmed, INC. | $327.32 | 2022-2025 | Arikayce |
| Genzyme Corporation | $241.47 | 2022-2025 | |
| Grifols USA, LLC | $189.31 | 2022-2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $187.16 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $146.67 | 2023-2025 | Aralast, Glassia |
| Actelion Pharmaceuticals US, INC. | $146.43 | 2022-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $108.74 | 2022-2025 | Trelegy Ellipta, Nucala |
| United Therapeutics Corporation | $101.74 | 2023-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.18 | 2023-2025 | Ofev, Jascayd |
| Viatris Specialty LLC | $91.53 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $67.30 | 2023-2025 | Zerbaxa, Recarbrio |
| Amgen INC. | $63.73 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $56.08 | 2023-2024 | Yupelri, Yupelri |
| Genentech USA, INC. | $54.27 | 2022-2024 | Xolair |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $53.31 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $46.53 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $41.33 | 2024 | Dupixent |
| Galvanize Therapeutics, INC | $36.43 | 2024 | Aliya System |
| Pfizer INC. | $35.45 | 2023-2024 | |
| Csl Behring | $34.53 | 2023-2024 | Kcentra |
| Tactile Systems Technology INC | $32.75 | 2025 | Flexitouch Plus, Nimbl |
| Boston Scientific Corporation | $32.74 | 2024 | Ekosonic |
| Astellas Pharma US INC | $22.31 | 2023 | Cresemba |
| Bayer Healthcare Pharmaceuticals INC. | $20.67 | 2025 | |
| Siemens Medical Solutions USA, INC. | $18.65 | 2024 | Cios Spin |
| Sandoz INC. | $17.20 | 2023 | Treprostinil |
| Philips North America LLC | $16.62 | 2024 | (Ak6) Vest Therapy |
| Chiesi USA, INC. | $16.06 | 2023 | Cleviprex, Kengreal |
| Verona Pharma, INC. | $15.04 | 2025 | Ohtuvayre |
| Electromed, INC. | $14.63 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dafang Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.